Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check12 days agoChange DetectedThe site revision identifier in the footer changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now displays a 403 Forbidden error instead of study content, signaling restricted access. A simple header and a Home link are shown.SummaryDifference18%

- Check33 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0 on the page, indicating an internal platform update. No study content or surrounding page information was modified.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page revision label changed from v3.6.5 to v3.6.6, indicating a new version of the page. It does not modify the study details, eligibility criteria, or results.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page revision updated from v3.6.4 to v3.6.5, indicating a small backend/template update rather than substantive changes to visible content.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.